F5R2 Aptamer Details
ID# 9577
Structure
Chemistry
DNA
Target
Alpha-syncuclein
Category
Protein
Affinity (Kd)
3.07 nM
Length
58 nucleotides
Aptazyme
No
Sequence (3-char table code)
G
A
C
U/T
dCpdGpdApdGpdTpdGpdGpdApdCpdGpdApdGpdTpdGpdCpdCpdTpdCpdCpdGpdGpdTpdApdCpdGpdApdGpdCpdTpdGpdTpdCpdTpdGpdApdTpdGpdGpdGpdTpdTpdTpdGpdCpdGpdCpdGpdCpdApdGpdGpdApdTpdCpdCpdAp-3'
Molecular Weight: 17986.6 g/mole
Extinction Coefficient: 552200
Binding Conditions / Buffer
binding and washing buffer (10 mM Tris-HCI, 1 mM EDTA,
2 M NaCI, pH7.5)
Binding Temp: 25°C
Refolding Protocol
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Reference
Zheng Y, J Qu, F Xue, Y Zheng, B Yang, Y Chang, H Yang
and J Zhang. (2018). Novel DNA aptamers for Parkinson’s
disease treatment inhibit a-synuclein aggregation and facilitate its degradation. Mol Ther Nucleic Acids 11:228–242.
Request a Quote
Have your aptamer oligo synthesized by Aptagen.
